Skip to main content
. 2013 Dec 30;35(5):1100–1109. doi: 10.1093/carcin/bgt489

Fig. 6.

Fig. 6.

DOPC nanoparticle delivery of EDD siRNA in vivo reduces tumor burden. (A) ES-2 or A2780ip2 cells were injected intraperitoneally into 40 female athymic nude mice per cell line. Mice were either treated with control siRNA in DOPC (lane 1), EDD siRNA1 in DOPC (lane 2), control siRNA in DOPC plus cisplatin (lane 3) or EDD siRNA1 in DOPC plus cisplatin (lane 4). Mice were treated for 4 weeks before killing and tumor collection. Tumors were excised and total tumor weight determined. The number above each lane represents the mean tumor weight in grams. Immunohistochemistry demonstrates EDD knockdown in vivo. A2780ip2 tumors from mice treated with (B) control siRNA in DOPC, (C) control siRNA in DOPC plus cisplatin, (D) EDD siRNA1 in DOPC and (E) EDD siRNA1 in DOPC plus cisplatin were immunostained with EDD antibody followed by horseradish peroxidase secondary antibody.